Uncoupling Protein-3 (UCP3) mRNA Expression in Reconstituted Human Muscle after Myoblast Transplantation in RAG2−/−/γc/C5− Immunodeficient Mice

Nolwen Guigal, Marianne Rodriguez, Raquel N. Cooper, Sandra Dromaint, James P. Di Santo, Vincent Mouly, Jean A. Boutin, Jean‐Pierre Galizzi

Journal of Biological Chemistry · 2002 · 16 citations · 28 references

DOIFull text

Open access

Concepts

Abstract

Uncoupling protein-3 (UCP3), which is expressed abundantly in skeletal muscle, is one of the carrier proteins dissipating the transmitochondrial electrochemical gradient as heat and has therefore been implicated in the regulation of energy metabolism. Myoblasts or differentiated muscle cells in vitro expressed little if any UCP3, compared with the levels detected in biopsies of skeletal muscle. In the present report, we sought to investigate UCP3 mRNA expression in human muscle generated by myoblast transplantation in the skeletal muscle of an immunodeficient mouse model. Time course experiments demonstrated that 7–8 weeks following transplantation fully differentiated human muscle fibers were formed. The presence of differentiated human muscle fibers was assessed by quantitative PCR measurement of the human α-actin mRNA together with immunohistochemical staining using specific antibodies for spectrin and the slow adult myosin heavy chain. Interestingly, we found that the expression of UCP3 mRNA was dependant on human muscle differentiation and that the UCP3 mRNA level was comparable with that found in human muscle biopsies. Moreover, the human UCP3 (hUCP3) promoter seems to be fully functional, since triiodothyronine treatment of the mice not only stimulated the mouse UCP3 (mUCP3) mRNA expression but also strongly stimulated the hUCP3 mRNA expression in human fibers formed after myoblast transplantation. To our knowledge, this is the first time that primary myoblasts could be induced to express the UCP3 gene at a level comparable of that found in human muscle fibers. Uncoupling protein-3 (UCP3), which is expressed abundantly in skeletal muscle, is one of the carrier proteins dissipating the transmitochondrial electrochemical gradient as heat and has therefore been implicated in the regulation of energy metabolism. Myoblasts or differentiated muscle cells in vitro expressed little if any UCP3, compared with the levels detected in biopsies of skeletal muscle. In the present report, we sought to investigate UCP3 mRNA expression in human muscle generated by myoblast transplantation in the skeletal muscle of an immunodeficient mouse model. Time course experiments demonstrated that 7–8 weeks following transplantation fully differentiated human muscle fibers were formed. The presence of differentiated human muscle fibers was assessed by quantitative PCR measurement of the human α-actin mRNA together with immunohistochemical staining using specific antibodies for spectrin and the slow adult myosin heavy chain. Interestingly, we found that the expression of UCP3 mRNA was dependant on human muscle differentiation and that the UCP3 mRNA level was comparable with that found in human muscle biopsies. Moreover, the human UCP3 (hUCP3) promoter seems to be fully functional, since triiodothyronine treatment of the mice not only stimulated the mouse UCP3 (mUCP3) mRNA expression but also strongly stimulated the hUCP3 mRNA expression in human fibers formed after myoblast transplantation. To our knowledge, this is the first time that primary myoblasts could be induced to express the UCP3 gene at a level comparable of that found in human muscle fibers. Uncoupling protein-3 (UCP3) 1The abbreviations used are: UCP3, uncoupling protein-3; hUCP3, human UCP3; T3, triiodothyronine; TA, tibialis anterior; RT, reverse transcriptase; MHC, myosin heavy chain; TRE, thyroid responsive element is a mitochondrial membrane protein that is predominantly expressed in human and rodent skeletal muscle and brown fat. The gene encoding UCP3 is located on human chromosome 11 and mouse chromosome 7 (1Solanes G. Vidal-Puig A. Grujic D. Flier J.S. Lowell B.B. J. Biol. Chem. 1997; 272: 25433-25436Google Scholar). The UCP3gene encodes for a protein with 60% homology to the brown fat-specific mitochondrial uncoupling protein UCP1 (2Vidal-Puig A. Solanes G. Grujic D. Flier J.S. Lowell B.B. Biochem. Biophys. Res. Commun. 1997; 235: 79-82Google Scholar, 3Boss O. Samec S. Paoloni-Giacobino A. Rossier C. Dulloo A. Seydoux J. Muzzin P. Giacobino J.P. FEBS Lett. 1997; 408: 39-42Google Scholar). The sequence similarity between UCP1 and UCP3 suggested to us that UCP3, like UCP1, might be a mitochondrial uncoupling protein involved in adaptive thermogenesis and energy expenditure in muscle. Moreover, biochemical experiments based on the overexpression of UCP3 in yeast or reconstituted transport activity of UCP3 in liposomes have confirmed the uncoupling activity of the UCP3 protein (4Zhang C.Y. Hagen T. Mootha V.K. Slieker L.J. Lowell B.B. FEBS Lett. 1999; 449: 129-134Google Scholar, 5Bouillaud F. Int. J. Obes. Relat. Metab. Disord. 1999; 23: S19-S23Google Scholar). Furthermore, a correlation between the increase in UCP3 protein in skeletal muscle and the nonphosphorylating mitochondrial respiration rates was demonstrated in rats by modulating their metabolic status via triiodothyronine (T3) levels. Despite accumulating evidence that UCP3 plays a role as a mitochondrial uncoupling protein, UCP3 does not appear to be involved in adaptive thermogenesis in rodents in response to cold exposure and diet. Moreover, the role of UCP3 in energy expenditure and uncoupling effect is subject to controversy. First, homozygousUCP3 −/− mice lacked the obese phenotype and displayed an unchanged metabolic rate in response to cold exposure, fasting, stress, or T3 (6Vidal-Puig A.J. Grujic D. Zhang C.Y. Hagen T. Boss O. Ido Y. Szczepanik A. Wade J. Mootha V. Cortright R. Muoio D.M. Lowell B.B. J. Biol. Chem. 2000; 275: 16258-16266Google Scholar, 7Gong D.W. Monemdjou S. Gavrilova O. Leon L.R. Marcus-Samuels B. Chou C.J. Everett C. Kozak L.P. Li C. Deng C. Harper M.E. Reitman M.L. J. Biol. Chem. 2000; 275: 16251-16257Google Scholar). Second, transgenic mice overexpressing human UCP3 (hUCP3) in skeletal muscle are hyperphagic and nonobese with increased energy expenditure (8Clapham J.C. Arch J.R. Chapman H. Haynes A. Lister C. Moore G.B. Piercy V. Carter S.A. Lehner I. Smith S.A. Beeley L.J. Godden R.J. Herrity N. Skehel M. Changani K.K. Hockings P.D. Reid D.G. Squires S.M. Hatcher J. Trail B. Latcham J. Rastan S. Harper A.J. Cadenas S. Buckingham J.A. Brand M.D. Abuin A. Nature. 2000; 406: 415-418Google Scholar), a phenotype that could result from some sort of UCP3 expression and uncoupling artifact (9Cadenas S. Echtay K.S. Harper J.A. Jekabsons M.B. Buckingham J.A. Grau E. Abuin A. Chapman H. Clapham J.C. Brand M.D. J. Biol. Chem. 2002; 277: 2773-2778Google Scholar) as had already been described in yeast (10Harper J.A. Stuart J.A. Jekabsons M.B. Roussel D. Brindle K.M. Dickinson K. Jones R.B. Brand M.D. Biochem. J. 2002; 361: 49-56Google Scholar). In humans, even though their impact on these phenotypes seems to be modest, several genetic analyses have shown an association between UCP3 gene polymorphism in basal lipid oxidation reduction (11Argyropoulos G. Brown A.M. Willi S.M. Zhu J. He Y. Reitman M. Gevao S.M. Spruill I. Garvey W.T. J. Clin. Invest. 1998; 102: 1345-1351Google Scholar) or body mass index in relation to morbid obesity or physical activity (12Otabe S. Clement K. Dubois S. Lepretre F. Pelloux V. Leibel R. Chung W. Boutin P. Guy-Grand B. Froguel P. Vasseur F. Diabetes. 1999; 48: 206-208Google Scholar, 13Otabe S. Clement K. Dina C. Pelloux V. Guy-Grand B. Froguel P. Vasseur F. Diabetologia. 2000; 43: 245-249Google Scholar). A new proposed role for UCP3 arose from several studies in rodents and humans showing that the UCP3 gene was up-regulated in physiological situations associated with high free fatty acid plasma levels such as starvation (14Gong D.W. He Y. Karas M. Reitman M. J. Biol. Chem. 1997; 272: 24129-24132Google Scholar, 15Millet L. Vidal H. Andreelli F. Larrouy D. Riou J.P. Ricquier D. Laville M. Langin D. J. Clin. Invest. 1997; 100: 2665-2670Google Scholar), postnatal development (16Brun S. Carmona M.C. Mampel T. Vinas O. Giralt M. Iglesias R. Villarroya F. FEBS Lett. 1999; 453: 205-209Google Scholar), or high fat diets (17Matsuda J. Hosoda K. Itoh H. Son C. Doi K. Tanaka T. Fukunaga Y. Inoue G. Nishimura H. Yoshimasa Y. Yamori Y. Nakao K. FEBS Lett. 1997; 418: 200-204Google Scholar). Fatty acids themselves when administered in vivoinduce UCP3 gene expression in both rodents and humans (18Brun S. Carmona M.C. Mampel T. Vinas O. Giralt M. Iglesias R. Villarroya F. Diabetes. 1999; 48: 1217-1222Google Scholar, 19Khalfallah Y. Fages S. Laville M. Langin D. Vidal H. Diabetes. 2000; 49: 25-31Google Scholar). Altogether, these data favor the hypothesis that the primary function of UCP3 in skeletal muscle may be to either passively or actively regulate the utilization of lipids as a fuel substrate. In muscle, UCP3 gene expression is regulated both by to the metabolic and the hormonal status. Multiple hormonal treatments in vivo, such as leptin, thyroid hormones, glucocorticoids, and especially peroxisome proliferator-activated receptors agonists, cause dramatic changes in UCP3 gene expression in muscle (14Gong D.W. He Y. Karas M. Reitman M. J. Biol. Chem. 1997; 272: 24129-24132Google Scholar) (18Brun S. Carmona M.C. Mampel T. Vinas O. Giralt M. Iglesias R. Villarroya F. Diabetes. 1999; 48: 1217-1222Google Scholar). Although studies have been carried out on the UCP3 promoter (20Acin A. Rodriguez M. Rique H. Canet E. Boutin J.A. Galizzi J.P. Biochem. Biophys. Res. Commun. 1999; 258: 278-283Google Scholar), the hormonal signals and responsive elements regulating UCP3 gene transcription in skeletal muscle have not yet been identified. One of the problems in characterizing this promoter is due to the fact that virtually all cultured muscle cells express little if any UCP3. These data suggest that specific transcriptional programs generating full muscle phenotype are exclusively activated in vivo but not in cultured muscle cells. Alternatively, in vivo muscle fibers might receive external signals triggering UCP3 gene expression (16Brun S. Carmona M.C. Mampel T. Vinas O. Giralt M. Iglesias R. Villarroya F. FEBS Lett. 1999; 453: 205-209Google Scholar). To study the mechanisms regulating hUCP3 gene transcription and identify cis-/trans-acting DNA elements, we searched for an experimental model that would express a hUCP3 mRNA at levels similar to that found in human skeletal muscle biopsies. In the present work, we have injected human myoblasts into the tibialis anterior (TA) of immunodeficient mice RAG2−/−/γc/C5− (21Cooper R.N. Irintchev A. Di Santo J.P. Zweyer M. Morgan J.E. Partridge T.A. Butler-Browne G.S. Mouly V. Wernig A. Hum. Gene Ther. 2001; 12: 823-831Google Scholar). In thisin vivo environment, injected cells proliferate and fuse to form muscle fibers that become innervated and contract. In these reconstituted muscles, we were able to detect normal levels of hUCP3 gene expression. Moreover, the hUCP3 promoter appears to be fully functional, since the effect of T3 on hUCP3 mRNA expression was similar to that found on mouse UCP3 (mUCP3) mRNA expression. To our knowledge, this is the first model that permits both the characterization of the hUCP3 promoter and the physiological function of the putative uncoupling protein UCP3. A biopsy from the quadriceps muscles of a 5-day-old infant was obtained during autopsy in accordance with the French legislation on ethical rules. From this biopsy, satellite cell populations were isolated from biopsies as described previously (22Decary S. Mouly V. Butler-Browne G.S. Hum. Gene Ther. 1996; 7: 1347-1350Google Scholar, 23Edom-Vovard F. Mouly V. Barbet J.P. Butler-Browne G.S. J. Cell Sci. 1999; 112: 191-199Google Scholar). These cells were expanded in growth medium, which consists of Ham's F-10 (Invitrogen) supplemented with 50 μg/ml of gentamycin and 20% fetal calf serum (Biomedia), and were called CHQ5B. The cells displayed a myogenic purity of 80%, as assessed by desmin staining (21Cooper R.N. Irintchev A. Di Santo J.P. Zweyer M. Morgan J.E. Partridge T.A. Butler-Browne G.S. Mouly V. Wernig A. Hum. Gene Ther. 2001; 12: 823-831Google Scholar, 24Kaufman S.J. Foster R.F. Proc. Natl. Acad. Sci. U. S. A. 1988; 85: 9606-9610Google Scholar). To induce myotube formation, confluent cultures were cultivated for 10 days in Dulbecco's modified Eagle's medium supplemented with 10 μg/ml of insulin (Sigma) and 100 μg/ml of transferrin (Invitrogen). Fifty-five immunodeficient RAG2−/−/γc− mice, 2–3 months old, were used in this study as recipients for human myoblast implantation. All experiments were carried out in the specific pathogen-free animal facilities at the Pasteur Institute. The cells used for transplantation (CHQ5B) were expanded to 20 population doubling levels. Prior to injection the cells were trypsinized, centrifuged (360 × g) and resuspended in growth medium. Sufficient aliquots of cells were prepared in siliconized Eppendorf tubes. Following additional centrifugation, the supernatant was aspirated leaving a pellet containing 5 × 105cells per injection. For implantation, the mice were anesthetized with hypnorm/hypnovel. The TA muscles of both hindlimbs were exposed, and the proximal and distal portions of the muscle received a localized frozen lesion for 10 s (25Irintchev A. Langer M. Zweyer M. Theisen R. Wernig A. J. Physiol. (Lond.). 1997; 500: 775-785Google Scholar). This was repeated three times before injecting the cells using a 5-μl Hamilton syringe. The cells were injected into three to five different sites along the length of the muscle. The skin was then closed with fine sutures. Mice were sacrificed at different weeks post-implantation, and the TA muscles were dissected, mounted in gum tragacanth (6% in water; Sigma), and frozen in isopentane precooled in liquid nitrogen or kept for mRNA extraction. Surgical procedures were performed under sterile conditions and in accordance with the legal regulations in France. Eight weeks after implantation, immunofluorescence staining on serial transverse cryostat sections (5 μm) of the TA muscle was performed using the Vector Mouse on Mouse (M.O.M.) immunodetection kit (Vector, Burlingame, CA). On unfixed sections, a human-specific monoclonal anti-spectrin (NCL-Spec1, Novacastra) antibody was used at a dilution of 1/50, and an anti-slow myosin (NCL-MHCs, Novacastra) antibody was used at a dilution of 1/5. Primary antibodies were visualized with either Alexa Fluor 488 or Alexa Fluor 594 conjugated to streptavidin (Molecular Probes, Montluçon, France). Images were digitalized using the Photometrics and MetaView image analysis system. Mice received a single T3 injection at 2.5, 10, and 100 μg/100 g body mass (in 100 μl), whereas the control received the vehicle only (5 mm NaOH). Injections were given intraperitoneally in the morning. The mice were sacrificed 24 h later, and the TA muscles were dissected and stored frozen for mRNA extraction. Total RNA was isolated from the TA of mice using the RNAXel kit (Eurobio, Paris, France). One microgram of total RNA was reverse-transcribed using the Moloney murine leukemia virus reverse transcriptase in 20 μl of its own buffer (Invitrogen) and oligo(dT) at 37 °C for 1 h. Quantitative real-time PCR was performed with a LightCycler using FastStart DNA Master SYBR GreenI (Roche Molecular Biochemicals). The cDNA product was amplified in a total volume of 20 μl with 0.5 μm of each primer, 4 mm MgCl2 (final concentration). All the primers were designed to anneal and amplify only mRNA. Moreover, primers were chosen to distinguish between human and mice sequences. The sequence primers are presented in TableI. A negative control for PCR consisted of omitting cDNA in the reaction tube. hUCP3 and α-actin levels were normalized to human β2-microglobulin and mUCP3 was normalized to mouse β2-microglobulin. This was noted REL for relative expression level.Table IPrimers sequence designed for and used in the quantitative PCR experiments for the measurement of the expression of mouse and human uncoupling protein-3 and control mouse α-actinPrimersForwardReverseHuman β2-microglobulin5′-GTG-TCT-GGG-TTT-CAT-CCA-TC-3′5′-AAT-GCG-GCA-TCT-TCA-ACC-TC-3′Mouse β2-microglobulin5′-TCA-GTA-ACA-CAG-TTC-CAC-CC-3′5′-GTT-CAA-ATG-AAT-CTT-CAG-AGC-AT-3′Human the primers were designed to anneal and amplify only mRNA. Moreover, primers were chosen to distinguish between human from mice sequences. in a new All the primers were designed to anneal and amplify only mRNA. Moreover, primers were chosen to distinguish between human from mice sequences. UCP3 mRNA levels were in cultures of human myoblasts and as as in human muscle biopsies using real-time in the levels of UCP3 expressed in both myoblasts and were that expressed in muscle biopsies. in human muscle the level of UCP3 mRNA was and that either in myoblasts or was virtually between and differentiated This would suggest that the in vitro conditions not to induce UCP3 expression to the level in skeletal muscle of UCP3 mRNA level in and in human muscle biopsies by real-time skeletal in a new myoblasts were injected into the TA muscle of an immunodeficient RAG2−/−/γc/C5− The presence of human muscle fibers in TA muscle was by using a antibody spectrin that the basal fibers 1 All mouse muscles after 1 of transplantation not The of muscle fibers containing human was by weeks after cell using the differentiation adult slow and mRNA of the α-actin using real-time The of and spectrin in skeletal muscle sections could be after transplantation The human α-actin was amplified by real-time using human-specific primers that not with the mouse that weeks after the α-actin mRNA level a level similar to that in the human muscle whereas in myoblast and cultured in the α-actin mRNA level and in human muscle biopsies. PCR of the α-actin product was not due to since PCR reverse transcriptase not any The of the PCR was assessed by with an mRNA expression was in −/− mouse tibialis muscle weeks following myoblast transplantation. mRNA expression was by real-time human muscle weeks after differentiated these that transplantation of human myoblasts into RAG2−/−/γc/C5− mouse muscles fully differentiated human muscle fibers that express UCP3. The hUCP3 mRNA level was after myoblast transplantation and at and These that the hUCP3 mRNA level increased between and 7 weeks after transplantation and then a at 7–8 at which time hUCP3 mRNA levels in human and human muscle biopsies were comparable Eight weeks after mice were injected intraperitoneally with T3, and 24 h the TA muscles were The in vivo effect of T3 on both human and mouse UCP3 mRNA expression is presented in T3 induced a increase in hUCP3 mRNA levels with and at 2.5, and 10 T3, 4 T3 induced a increase in mUCP3 mRNA levels with and at 2.5, and 10 T3, 4 In this study we described for the first time an model study UCP3 gene expression in human In this following transplantation of human myoblasts into the TA muscle of immunodeficient mice human muscle fibers were formed. human myoblasts were cultured using vitro UCP3 gene expression was compared with its expression in from quantitative experiments that in human muscle biopsies the level of UCP3 mRNA was and that in either myoblasts or a level of expression of UCP3 mRNA is a of muscle cells in and has also been in and murine I. S. Y. K. T. M. FEBS Lett. 1999; Scholar, M.D. Biochem. Biophys. Res. Commun. 1999; 258: Scholar). In vitro differentiated skeletal muscle cells form but their gene expression are different to that of muscle For is expressed in R.B. P. G. Proc. Natl. Acad. Sci. U. S. A. 2001; Scholar), whereas expression be in muscle The in the present study is that the hUCP3 mRNA level was fully by transplantation of human myoblasts in the TA of an immunodeficient This model permits transplantation for of time to of muscle cells. In this we first confirmed that transplantation of human myoblast into TA muscle of RAG2−/−/γc/C5− mice fully differentiated human muscle fibers. The expression of human spectrin and differentiation the human α-actin and the slow adult weeks confirmed the presence of human muscle fibers muscles in the TA of RAG2−/−/γc/C5− Second, we that transplantation of human myoblasts the expression of the human UCP3 gene from a level in myoblast to a level similar to that found in human muscle biopsies. In the reconstituted human skeletal muscle UCP3 gene expression a that a at 7–8 weeks together these that an increase in UCP3 gene expression at 7–8 weeks following human myoblast transplantation was associated with in vivo human muscle cell differentiation and The also suggest that an additional specific in vivo transcriptional is to UCP3 gene expression. Alternatively, in vivo signals in vitro might in UCP3 gene expression. studies have shown that T3 treatment strongly UCP3 gene expression in rodent and human skeletal we found that T3 treatment increased UCP3 mRNA in a in human the effect of T3 on UCP3 gene expression. In UCP3 gene regulation by T3 in humans and mice as T3 treatment both human and mouse UCP3 to a similar mechanisms could for the effect of T3 on UCP3 gene expression. The hUCP3 promoter a sequence that by a single from the thyroid response element (20Acin A. Rodriguez M. Rique H. Canet E. Boutin J.A. Galizzi J.P. Biochem. Biophys. Res. Commun. 1999; 258: 278-283Google Scholar), but is not this putative is Interestingly, the mUCP3 promoter might also a similar the of human myoblasts the hUCP3 promoter to the putative Despite the of on UCP3, the UCP3 gene expression in human skeletal muscle This might be due to the fact that all studies at characterizing UCP3 promoter were carried vitro the UCP3 gene is to identify the elements UCP3 gene The to UCP3 gene expression in differentiated human myoblast in vitro has not yet been on this myoblast transplantation into immunodeficient mouse skeletal muscles appears to be the model of to study hUCP3 gene regulation and its based on promoter to that hUCP3 gene expression with a to in obesity are to D. and E. for in vivo also J. and C. for and

References

28